# A Study of Herceptin (Trastuzumab) Monotherapy in Patients With Metastatic Urothelial Cancer

> **NCT02013765** · PHASE2 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 5 (actual)

## Conditions studied

- Urinary Tract Cancer

## Interventions

- **DRUG:** trastuzumab

## Key facts

- **NCT ID:** NCT02013765
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2001-01
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Trial was terminated prematurely because of recruitment difficulties.
- **Last updated:** 2014-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02013765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02013765, "A Study of Herceptin (Trastuzumab) Monotherapy in Patients With Metastatic Urothelial Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02013765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*